DNA methylation of KIFC1 gene in determination of histological diagnosis, prognosis and metastasis of lung cancer

ArticleAçık Erişim

Özet

Background: One of the main features of cancer, especially lung cancer (LC), is abnormal cell division. Abnormal expression of kinesin family member C1 (KIFC1/HSET), which is involved in mitotic cell division and ensures equatorial alignment of chromosomes during division, is observed in both premalignant and malignant lesions. There are no studies in the literature addressing the role of KIFC1 in the diagnosis and follow-up of LC. In this study, we investigated the epigenetic role of KIFC1 in the diagnosis, stage, and prognosis of various histological subtypes diagnosed with LC. Material and Methods: The expression and methylation status of the KIFC1 gene were examined after DNA/RNA isolation in tumor, conjugate normal tissue, and blood samples from 39 patients diagnosed with LC and in blood samples from 39 healthy controls. Changes in KIFC1 gene expression were examined by the Quantitative Real Time-PCR (qRT-PCR) method after cDNA synthesis following RNA isolation. The Methylation-Specific PCR (MSP) method was used to determine the methylation status of the KIFC1 gene. In this study, the expression/methylation profiles of the KIFC1 gene and the clinical and pathological characteristics of the patients were analyzed by statistical methods. Result: Hypomethylation was detected in 95.8% of the 62.1% of patients’ tissues with increased KIFC1 gene expression. The expression level of the KIFC1 gene was found to be increased 3.2-fold in the tumor tissues of the patients compared with the conjugated normal tissues and 2.4-fold in the serum of the patients compared with the healthy serum. Statistical comparison of patients' clinical parameters and methylation and expression results revealed statistical significance between KIFC1 expression and metastasis, tumor stage and tumor grade. Conclusion: In conclusion, the increase in the expression level of the KIFC1 gene is higher in patients diagnosed with LC than in the healthy population, and therefore, the increase in the expression level of the KIFC1 gene due to hypomethylation can be used as a screening biomarker in LC. It can also be considered that the methylation profile of the KIFC1 gene may be a potential biomarker for determining the subtype of squamous cell carcinoma in LC. The results of the study need to be analyzed and continued with a larger number of patients. © 2023 Elsevier GmbH

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/12047Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1016/j.prp.2023.154742Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorCelik, Betul
dc.contributor.authorPasin, Ozge
dc.contributor.authorSen, Sena
dc.contributor.authorTuncer, Seref Bugra
dc.contributor.authorKayım, Zubeyde Yalnız
dc.contributor.authorErciyas, Seda Kılıc
dc.contributor.authorErdogan, Ozge Sukruoglu
dc.contributor.authorGultaslar, Busra Kurt
dc.contributor.authorGhafour, Arash Adamnejad
dc.contributor.authorYazıcı, Hulya
dc.contributor.authorOlgac, Necat Vakur
dc.date.accessioned2026-10-18T20:27:00.134590173Z
dc.date.available2026-10-18T20:27:00.134590173Z
dc.date.issued2023
dc.description.abstractBackground: One of the main features of cancer, especially lung cancer (LC), is abnormal cell division. Abnormal expression of kinesin family member C1 (KIFC1/HSET), which is involved in mitotic cell division and ensures equatorial alignment of chromosomes during division, is observed in both premalignant and malignant lesions. There are no studies in the literature addressing the role of KIFC1 in the diagnosis and follow-up of LC. In this study, we investigated the epigenetic role of KIFC1 in the diagnosis, stage, and prognosis of various histological subtypes diagnosed with LC. Material and Methods: The expression and methylation status of the KIFC1 gene were examined after DNA/RNA isolation in tumor, conjugate normal tissue, and blood samples from 39 patients diagnosed with LC and in blood samples from 39 healthy controls. Changes in KIFC1 gene expression were examined by the Quantitative Real Time-PCR (qRT-PCR) method after cDNA synthesis following RNA isolation. The Methylation-Specific PCR (MSP) method was used to determine the methylation status of the KIFC1 gene. In this study, the expression/methylation profiles of the KIFC1 gene and the clinical and pathological characteristics of the patients were analyzed by statistical methods. Result: Hypomethylation was detected in 95.8% of the 62.1% of patients’ tissues with increased KIFC1 gene expression. The expression level of the KIFC1 gene was found to be increased 3.2-fold in the tumor tissues of the patients compared with the conjugated normal tissues and 2.4-fold in the serum of the patients compared with the healthy serum. Statistical comparison of patients' clinical parameters and methylation and expression results revealed statistical significance between KIFC1 expression and metastasis, tumor stage and tumor grade. Conclusion: In conclusion, the increase in the expression level of the KIFC1 gene is higher in patients diagnosed with LC than in the healthy population, and therefore, the increase in the expression level of the KIFC1 gene due to hypomethylation can be used as a screening biomarker in LC. It can also be considered that the methylation profile of the KIFC1 gene may be a potential biomarker for determining the subtype of squamous cell carcinoma in LC. The results of the study need to be analyzed and continued with a larger number of patients. © 2023 Elsevier GmbH
dc.description.sponsorship“This work was supported by the Scientific Research Projects Coordination Unit of Istanbul University .” Project number: 36429 .
dc.identifier.doi10.1016/j.prp.2023.154742
dc.identifier.eissn1618-0631
dc.identifier.issn0344-0338
dc.identifier.pmid37666088
dc.identifier.scopus2-s2.0-85169605295
dc.identifier.startpage154742
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/12047
dc.identifier.volume249
dc.identifier.wosWOS:001071621100001
dc.language.isoen
dc.publisherElsevier GmbH
dc.relation.ispartofPathology Research and Practice
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBiomarker
dc.subjectExpression
dc.subjectKIFC1
dc.subjectLung cancer
dc.subjectMethylation
dc.subjectCarcinoma, Squamous Cell
dc.subjectDNA Methylation
dc.subjectEpigenomics
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectPrognosis
dc.subjectbiological marker
dc.subjectkinesin
dc.subjectkinesin family member C1
dc.subjectunclassified drug
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectblood sampling
dc.subjectcancer grading
dc.subjectcancer patient
dc.subjectcancer prognosis
dc.subjectcancer staging
dc.subjectcancer tissue
dc.subjectclinical article
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectDNA isolation
dc.subjectDNA synthesis
dc.subjectfemale
dc.titleDNA methylation of KIFC1 gene in determination of histological diagnosis, prognosis and metastasis of lung cancer
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus5
rdl.citation.wos4
rdl.departmentIstanbul University, Institute of Graduate Studies in Health Sciences, Department of Cancer Genetics, Istanbul, Türkiye
rdl.departmentDepartment of Cancer Genetics, Istanbul Faculty of Medicine, Oncology Institute, Istanbul University, Istanbul, Türkiye
rdl.departmentMolecular Biology Department, Erzincan Binali Yıldırım University, Erzincan, Türkiye. Electronic address: celikbetul6@gmail.com.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)